Information  X 
Enter a valid email address

Sage Group PLC (SGE)

  Print      Mail a friend       Annual reports

Thursday 19 March, 2020

Sage Group PLC

Transaction in Own Shares

RNS Number : 7251G
Sage Group PLC
19 March 2020
 

The Sage Group plc ("Sage" or the "Company") today announces that on 18 March 2020 it purchased a total of 106,881 of its ordinary shares of 1 ⁴/₇ pence each, as further detailed below.

 

 

 

 

 

 

 

 

 

Per Ordinary Share

 

 

 

 

 

Average price paid

£5.9031

 

 

 

 

 

Highest price paid

£6.0640

 

 

 

 

 

Lowest price paid

£5.7220

 

 

 

 

 

 

 

 

 

 

 

These share purchases form part of the Company's share buy-back programme, which has now been suspended, details of which were announced on 12 March 2020 and subsequently on 18 March 2020.

The Company will hold the purchased shares in treasury, to be used to meet obligations arising from share option programmes or other allocations of shares to employees or directors.

Following the above transaction, the issued share capital of Sage consists 1,120,789,295 ordinary shares of 1⁴/₇pence each, of which 30,242,603 ordinary shares of 1⁴/₇pence each would be held in treasury. Therefore, the total exercisable voting rights in Sage will be 1,090,546,692.

The above figure 1,090,546,692 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Sage under the DTRs. In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), a schedule of individual trades by Citigroup is available using the following link:

http://www.rns-pdf.londonstockexchange.com/rns/7251G_1-2020-3-19.pdf

 

 

 

 

End

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
POSEAEDNFSSEEEA

a d v e r t i s e m e n t